TSRL, INC.
Ann Arbor, MI · Medtech
Transdermal microneedle patch for delivery of zanamivir (antiviral drug) to treat influenza
- Grants
- $27M
- 30 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 0 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Broad Spectrum Antiviral Nucleoside Phosphonate Analogs | $2,987,766 | |
| Federal grant | Department of Health and Human Services · Phase I · Nucleoside Phosphonate Analogs for the Treatment of Adenoviral Infection | $299,360 | |
| Federal grant | Department of Health and Human Services · Phase II · Broad Spectrum Antiviral Nucleoside Phosphonate Analogs | $990,162 | |
| Federal grant | Department of Health and Human Services · Phase II · Broad Spectrum Antiviral Nucleoside Phosphonate Analogs | $999,700 | |
| Federal grant | Department of Health and Human Services · Phase I · Microneedle Delivery of Zanamivir for Treatment of Influenza Infections | $572,526 | |
| Federal grant | Department of Health and Human Services · Phase I · Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections | $583,958 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Microneedle Delivery of Zanamivir for Treatment of Influenza Infections | $284,761 | |
| Federal grant | Department of Health and Human Services · Phase I · Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections | $983,590 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections | $299,733 | |
| Federal grant | Department of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for Treatment of Influenza | $998,654 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections | $971,090 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections | $270,047 | |
| Federal grant | Department of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for Treatment of Influenza | $971,504 | |
| Federal grant | Department of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for Treatment of Influenza | $952,176 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis | $1,632,248 | |
| Federal grant | Department of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | $1,999,466 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel, Safe, Efficacious Heparin Reversal | $394,392 | |
| Federal grant | Department of Health and Human Services · Phase I · Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease | $299,620 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis | $643,779 | |
| Federal grant | Department of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | $999,604 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections. | $998,521 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections. | $997,670 | |
| Federal grant | Department of Health and Human Services · Phase II · Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | $998,663 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu | $999,746 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections. | $999,765 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu | $999,975 | |
| Federal grant | Department of Health and Human Services · Phase II · Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease | $1,097,498 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1294 | PARATECHS CORP | — | — |
| 1295 | SCALAR MAGNETICS, LLC | — | — |
| 1296 | Vital Connect, Inc. | — | $83M |
| 1297 | TSRL, INC. | — | — |
| 1298 | Activated Research Company, LLC | — | — |
| 1299 | Fractyl Health | — | $274M |
| 1300 | CAMBIUM MEDICAL TECHNOLOGIES, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Swellable Hydrogel Microneedles Backed By A Drug Reservoir Patchapplication
- Swellable Hydrogel Microneedles Backed By A Drug Reservoir Patchapplication
- Metabolically Stable Prodrugsapplication
- Metabolically Stable Prodrugsapplication
- Neuraminidase Inhibitorsapplication
- Prodrugs Of Neuraminidase Inhibitorsapplication
- Prodrugs Of Triciribine And Triciribine Phosphateapplication
- Prodrug Compositionapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.